Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.

Autor:	Yildirim ME; Medical Oncology Department, İstanbul Dr. Lütfi Kırdar Kartal City Hospital, Istanbu, Türkiye., Karadurmuş N; Medical Oncology Department, Gulhane Training and Research Hospital, Ankara, Türkiye., Ökten İN; Medical Oncology Department, Medeniyet University Goztepe Training and Research Hospital, Istanbul, Türkiye., Türk HM; Department of Medical Oncology, Bezmialem Vakif University Faculty of Medicine, Istanbul, Türkiye., Urakçı Z; Department of Medical Oncology, Dicle University Medical Faculty, Diyarbakir, Türkiye., Arslan Ç; Medical Oncology, Bahcesehir Universitesi Tip Fakultesi, Istanbul, Türkiye., Çelik S; Medical Oncology Department, Istanbul Oncology Hospital, Istanbul, Türkiye., Dane F; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Türkiye., Şendur MAN; Medical Oncology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Türkiye., Bilir C; Medical Oncology Department, Sakarya University Training and Research Hospital, Sakarya, Türkiye., Karabulut B; Medical Oncology, Ege University Faculty of Medicine, Izmir, Türkiye., Cicin İ; Department of Internal Medicine, Division of Oncology, Trakya University Faculty of Medicine, Edirne, Türkiye., Çubukçu E; Faculty of Medicine, Medical Oncology, Uludag University, Bursa, Türkiye., Karaca M; Medical Oncology Department, Antalya Training and Research Hospital, Antalya, Türkiye., Ozcelik M; Department of Oncology, Umraniye Training and Research Hospital, Istanbul, Türkiye., Artaç M; Department of Medical Oncology, Necmettin Erbakan University Medical Faculty, Konya, Türkiye., Tanrikulu E; Medical Oncology, Istanbul Haydarpasa Numune Training and Research Hospital, Istanbul, Türkiye., Alacacioglu A; Medical Oncology Department, Ministry of Health İzmir Katip Çelebi University Atatürk Education and Research Hospital, Izmir, Türkiye., Açıkgöz Ö; Medical Oncology Department, Istanbul Medipol University, İstanbul, Türkiye., Öven B; Medical Oncology Department, Yeditepe University Hospital, Istanbul, Türkiye., Geredeli Ç; Department of Medical Oncology, Okmeydani Training and Research Hospital, Istanbul, Türkiye., Çil T; Department of Medical Oncology, University of Health Sciences, Adana City Education and Research Hospital, Adana, Türkiye., Harputluoğlu H; Medical Oncology Department, İnönü Üniversitesi, Malatya, Türkiye., Kefeli U; Medical Oncology, Kocaeli University School of Medicine, Kocaeli, Türkiye., Bozkurt O; Medical Oncology Department, Erciyes Universitesi, Kayseri, Türkiye., Tural D; Medical Oncology, Istanbul Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Türkiye., Sakin A; Department of Medical Oncology, Yuzuncu Yil University, Van, Türkiye., Yalçın Ş; Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Türkiye., Gumus M; Department of Medical Oncology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Türkiye.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Apr 13, pp. 10781552241241004. Date of Electronic Publication: 2024 Apr 13.
DOI:	10.1177/10781552241241004
Abstrakt:	Backgrounds and Objectives: Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311). Materials and Methods: In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented. Patients were categorized into groups based on their second-line biological treatments: anti-EGFR (Group A and Group B, panitumumab and cetuximab) and anti-VEGF (Group C, bevacizumab and aflibercept). They were then compared within these groups. Results: A total of 588 patients with documented RAS wild-type status were evaluated. The median OS was 15.7, 14.3 and 14.7 months in Group A, Group B and Group C, respectively ( p   =  0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/aflibercept were 7.8, 6.6 and 7.4 months, respectively ( p   =  0.848). Conclusion: According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments. Competing Interests: Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu